Helmholtz Gemeinschaft


M01 as a novel drug enhancer for specifically targeting the blood-brain barrier

PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
[img] Other (Supplementary Material)

Item Type:Article
Title:M01 as a novel drug enhancer for specifically targeting the blood-brain barrier
Creators Name:Breitkreuz-Korff, O. and Tscheik, C. and Del Vecchio, G. and Dithmer, S. and Walther, W. and Orthmann, A. and Wolburg, H. and Haseloff, R.F. and Schröder, L. and Blasig, I.E. and Winkler, L.
Abstract:Drug delivery to the brain is limited for most pharmaceuticals by the blood-brain barrier (BBB) where claudin-5 dominates the paraendothelial tightening. For circumventing the BBB, we identified the compound M01 as a claudin-5 interaction inhibitor. M01 causes transient permeabilisation of the BBB depending on the concentration of small molecules in different cell culture models within 3 to 48 h. In mice, brain uptake of fluorescein peaked within the first 3 h after M01 injection and normalised within 48 h. Compared to the cytostatic paclitaxel alone, M01 improved delivery of paclitaxel to mouse brain and reduced orthotopic glioblastoma growth. Results on interactions of M01 with claudin-5 were incorporated into a binding model which suggests association of its aromatic parts with highly conserved residues of the extracellular domain of claudin-5 and adjacent transmembrane segments. Our results indicate the following mode of action: M01 preferentially binds to the extracellular claudin-5 domain, which weakens trans-interactions between adhering cells. Further decrease in membranous claudin-5 levels due to internalization and transcriptional downregulation enables the paracellular passage of small molecules. In summary, the first small molecule is introduced here as a drug enhancer, which specifically permeabilises the BBB for a sufficient interval for allowing neuropharmaceuticals to enter the brain.
Keywords:Drug Delivery, Claudin, Tight Junctions, Blood-Brain Barrier, Small Molecule, Permeability Enhancer, beta-Catenin, Glioblastoma, Animals, Mice
Source:Journal of Controlled Release
Page Range:137-148
Date:10 August 2021
Official Publication:https://doi.org/10.1016/j.jconrel.2021.08.014
PubMed:View item in PubMed

Repository Staff Only: item control page


Downloads per month over past year

Open Access
MDC Library